Jupiter Topco’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jupiter Topco’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.1M	Buy	+3,085,906	New	+$55.9M	0.02%	402

Other funds holding MLTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jupiter Topco's MLTX Position: Q2 2026 in Review

Jupiter Topco opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 3,085,906 shares worth $60.1M. The stake represents 0.02% of the portfolio and ranks #402 among its holdings.

159 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Jupiter Topco held 3,085,906 shares of MoonLake Immunotherapeutics worth $60.1M as of Q2 2026.
MoonLake Immunotherapeutics was a new Jupiter Topco position in Q2 2026.
MoonLake Immunotherapeutics made up 0.02% of Jupiter Topco's portfolio in Q2 2026, its #402 holding.
159 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.